FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileEstrella Immunopharma, Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
ESLAW
Estrella Immunopharma, Inc. Stock AnalysisComprehensive stock analysis for Estrella Immunopharma, Inc. (ESLAW) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisESLAW
ESLAW
Estrella Immunopharma, Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
ESLAW
  1. Home
  2. Stocks
  3. Estrella Immunopharma, Inc.

Estrella Immunopharma, Inc.

🇺🇸ESLAW•NASDAQ

Estrella Immunopharma, Inc.

🇺🇸ESLAW•NASDAQ
Market cap
$19.41M

Your view on ESLAW

Mkt Cap
$19.41M
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Estrella Immunopharma, Inc.

Industry
Biotechnology
Sector
Healthcare
CEO
Cheng Liu
Headquarters
5858 Horton Street, EmeryVille, CA, US
Industry
Biotechnology
Sector
Healthcare
CEO
Cheng Liu
Headquarters
5858 Horton Street, EmeryVille, CA, US
Description

Estrella Immunopharma, Inc. is an early-stage biopharmaceutical firm based in Emeryville, California, dedicated to advancing T-cell immunotherapies for various hematological malignancies and solid tumors within the United States.

Its lead investigational treatments include EB103, currently undergoing preclinical assessment for diffuse large B-cell lymphoma, and EB104, which targets both diffuse large B-cell lymphoma and acute lymphocytic leukemia.

The company also collaborates with Imugene Limited to develop solid tumor therapies, integrating Imugene's candidate CF33-CD19t with Estrella's EB103.

Financial Data

Stock Data

Price chart, volume, and trading data.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Estrella Immunopharma, Inc.. Starting points for Estrella Immunopharma, Inc.: EPS -$0.29, beta -0.09 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Estrella Immunopharma, Inc.. Trailing twelve-month EPS for Estrella Immunopharma, Inc. stands at -$0.29. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Estrella Immunopharma, Inc.. Estrella Immunopharma, Inc. has reported as a listed company since 2023. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold ESLAW12 companies
More Biotechnology companies
TickerTypeCompanySectorExchangeMkt cap
AURXNuo Therapeutics, Inc.HealthcareOTC$72.4M
AUTLAutolus Therapeutics plcHealthcareNASDAQ$241.7M
AVBPArriVent BioPharma, Inc. Common StockHealthcareNASDAQ$544.1M
AVCTFAvacta Group PlcHealthcareOTC$372.9M
AVE.AXAvecho Biotechnology LimitedHealthcareASX—
AVEFFAvecho Biotechnology LimitedHealthcareOTC$13.4M
AVIRAtea Pharmaceuticals, Inc.HealthcareNASDAQ$318.0M
AVLNAvalyn Pharma Inc. Common StockHealthcareNASDAQ$1.3B
AVTXAvalo Therapeutics, Inc.HealthcareNASDAQ$390.9M
AVXLAnavex Life Sciences Corp.HealthcareNASDAQ$54.8M
AXIMAXIM Biotechnologies, Inc.HealthcareOTC$3.7M
AXSMAxsome Therapeutics, Inc.HealthcareNASDAQ$6.8B
Ownership & News

Institutional Ownership

Which funds and firms own the stock.

About this section

Which institutions hold Estrella Immunopharma, Inc., and how their positions are changing. At a $19.4M market value, institutional positions materially move Estrella Immunopharma, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.

Insider Trading

Recent buying and selling by company executives.

About this section

Buying and selling by Estrella Immunopharma, Inc. executives and directors. Shares of Estrella Immunopharma, Inc. have traded between $0.06 and $0.11 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Estrella Immunopharma, Inc.. Coverage tracks Estrella Immunopharma, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Estrella Immunopharma, Inc.

ESLAW AnalysisFair
Past
1
Growth
2
Health
5
Profit
1
Value
1